Lisa Swanson, MD, PhD

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.

Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss take a closer look at the TRuE-AD1 and TRuE AD2 phase 3 trial and provide context regarding ruxolitinib cream for the treatment of atopic dermatitis in the clinical setting.

James Q Del Rosso, DO, takes a closer look at the trial data regarding timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss the week 8 change results of ruxolitinib cream from the TRuE-AD1 and TRuE AD2 phase 3 trial.

Thought leaders provide an overview of the basline characteristics of the TRuE-AD1 and TRuE AD2 phase 3 trial.

Dermatology experts review the design of the TRuE-AD1 and TRuE AD2 phase 3 trial.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, provide an overview of atopic dermatitis and review the burden of disease.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the impact of recent advances in atopic dermatitis treatment and look to future possibilities.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the challenges of identifying the right regimens for patients and the many factors that influence treatment selection.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, discuss how to talk about safety concerns with patients.

Experts share clinical insights boxed warning for the JAK inhibitor drug class.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the burden of itch in atopic dermatitis, and why JAK inhibitors may be able to provide relief.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, talk about the use of oral systemic agents and what they’ve learned about the patient experience from the use of these agents.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, examine the clinical context for the approval of topical ruxolitinib and its role in the treatment armamentarium.

Thought leaders discuss why JAK inhibitors are well suited for the management of itch and inflammation in the treatment of moderate to severe atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the recent trajectory of the atopic dermatitis therapeutic spectrum, notably how several newer approvals have changed how clinicians approach treatment.